Search company, investor...
MedImmune company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acq - P2P | Acquired



About MedImmune

MedImmune develops and markets products that address medical needs in areas such as infectious disease, immune regulation and cancer.

MedImmune Headquarters Location

One MedImmune Way

Gaithersburg, Maryland, 20878,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MedImmune

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MedImmune is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

MedImmune Patents

MedImmune has filed 378 patents.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Molecular biology, Biotechnology, Gene expression, Genetics


Application Date


Grant Date



Related Topics

Transcription factors, Molecular biology, Biotechnology, Gene expression, Genetics



Latest MedImmune News

Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer

Sep 14, 2022

News provided by Share this article Share this article BOSTON, Sept. 14, 2022 /PRNewswire/ -- Biolojic Design, a pioneer in the use of artificial intelligence (AI) in antibody design, today announced the appointment of Ronald Herbst, Ph.D. as Chief Scientific Officer, effective October 3, 2022. A 28-year industry veteran with a proven track record of scientific leadership in Big Pharma and small publicly traded biotechnology companies, Dr. Herbst joins Biolojic Design as the company is expanding its U.S. operations and advancing more computationally designed, smart antibodies into the clinic. Ronald Herbst, Ph.D., Chief Scientific Officer "Having an accomplished scientist and drug developer of Dr. Herbst's caliber at the helm of our U.S. hub demonstrates our commitment to delivering smart therapeutics to patients," said Yanay Ofran, Ph.D., Founder and Chief Executive Officer of Biolojic Design. "Ron brings an unmatched blend of executive experience, intimate understanding of cancer and immunology, and a proven track record in drug development. He will play an important role in expanding our U.S. operations and realizing our vision of bringing our AI-designed, smart antibodies into the clinic. "I am thrilled and honored to join the team at Biolojic Design and contribute to the inspiring work that Yanay and his team have been pursuing over the past ten years," said Dr. Herbst. "The ability to computationally redesign human antibodies and give them new, never before seen capabilities can revolutionize the treatment of cancer and immunological diseases. The ingenuity at the core of Biolojic Design brings together the best of the biotech and tech industries. I look forward to working with Yanay and the team at Biolojic Design to shepherd a whole new generation of smart therapeutics." During his 28-year career in the biopharmaceutical industry, Dr. Herbst has applied his expertise to multiple companies and development opportunities, spanning from early-stage to globally established companies. As CSO at Pyxis Oncology, Dr. Herbst was responsible for building out the company's research team and guiding its transition into a clinical-stage company. During his tenure at Pyxis, the company also completed an initial public offering (IPO) that raised $168 million. Previously, he served as Vice President of Research and Development and Head of Oncology Research at MedImmune, the global biologics research and development arm of AstraZeneca, and under his leadership, the oncology group brought 10 novel targets to the clinic. Dr. Herbst's earlier work at MedImmune focused on the respiratory, inflammation, and autoimmunity areas, where he helped to advance four novel molecules into the clinic. Before joining MedImmune, Dr. Herbst served as Senior Principal Investigator in oncology at DNAX, a Schering-Plough biotechnology subsidiary. After earning his Ph.D. at the Ludwig-Maximilian University of Munich, Dr. Herbst conducted his postdoctoral research in the Department of Biology at Stanford University. Dr. Herbst has (co)-authored more than 100 publications and is co-inventor on 17 pending or granted patents. About Biolojic Design Biolojic Design is committed to curing patients by designing and developing a pipeline of revolutionary therapeutics. Powered by AI, Biolojic's technology designs single and multi-specific antibodies precisely targeting predefined epitopes to execute novel biological programs. Focusing on cancer and autoimmune diseases, Biolojic develops a pipeline of antibodies that are designed to unlock the full potential of well-studied pathways. To learn more, please visit . Media Inquiries:  Tzahi Hoffman, Gitam Porter Novelli, +972-052-6633399 SOURCE Biolojic Design

  • When was MedImmune founded?

    MedImmune was founded in 1987.

  • Where is MedImmune's headquarters?

    MedImmune's headquarters is located at One MedImmune Way, Gaithersburg.

  • What is MedImmune's latest funding round?

    MedImmune's latest funding round is Acq - P2P.

  • Who are the investors of MedImmune?

    Investors of MedImmune include AstraZeneca, HBM Healthcare Investments, HBM Partners, Bellevue Asset Management, Investor Growth Capital and 5 more.

  • Who are MedImmune's competitors?

    Competitors of MedImmune include ISA Pharmaceuticals, CoImmune, Tetraphase Pharmaceuticals, Rigel Pharmaceuticals, Akebia Therapeutics and 13 more.

You May Also Like

Catena Pharmaceuticals

Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states.

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Bexion Pharmaceuticals

Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.


ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.


MIDA, LLC is a research and development drug therapeutic company focused on infectious disease indications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.